Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021
Vaccitech plc (NASDAQ: VACC) announced two poster presentations at AASLD’s Liver Meeting® 2021, showcasing clinical data for VTP-300, its immunotherapeutic for chronic hepatitis B virus (HBV) infection. The presentations include interim results from a Phase 1 study on ChAdOx1-HBV and a Phase 1b/2a study combining ChAdOx1/MVA vaccination with low-dose nivolumab. These findings will be presented virtually from November 12-15, 2021, highlighting progress in developing innovative treatments for HBV.
- Presentation of interim results from Phase 1 study indicating potential effectiveness of VTP-300.
- Partnership with recognized institutions like the University of Oxford for vaccine development.
- None.
OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLD’s Liver Meeting® 2021 showcasing clinical data for VTP-300, the Company’s immunotherapeutic in development for the treatment of chronic hepatitis B virus (HBV) infection. The Liver Meeting will be held virtually on November 12-15, 2021.
Poster Title: Interim results of HBV001, a Phase 1 study evaluating the safety and tolerability of therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection
Publication Number: 833
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Tamsin Cargill, Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, UK
Poster Title: Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB under nucleos(t)ide analogues
Publication Number: 835
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Thomas Evans, M.D., Chief Scientific Officer, Vaccitech plc
About Vaccitech plc.
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding: the timing and planned announcement of data from the Company’s VTP-300 program. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, the Company’s ability to fund its operations and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials and preclinical studies and other risks identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Quarterly Report on Form 10-Q for the first quarter of 2021 and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com
Robert Flamm, Ph.D. / Harrison Wong (US)
Burns McClellan, Inc.
212-213-0006 ext. 364 / 316
Email: rflamm@burnsmc.com / hwong@burnsmc.com
Henry Hodge, Vaccitech
Email: henry.hodge@vaccitech.co.uk
FAQ
What is Vaccitech's VTP-300?
When will Vaccitech present data on VTP-300?
What are the results of the Phase 1 study for VTP-300?
Where is the AASLD’s Liver Meeting 2021 being held?
Who presented the findings for Vaccitech's VTP-300 at the conference?
